EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review

Dusan Harmacek, Elena Rho, Seraina von Moos, Severin Simmler, Thomas Welte, Fabian Rössler, Thomas Schachtner, Lukas Weidmann

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70719 ↗

At a glance

Übersichtsarbeit in Clinical Transplantation, 2026. Written by Dusan Harmacek and 7 co-authors. Institution: Division of Nephrology, University Hospital Zurich, Zurich, Switzerland. Major MEDLINE topics: Abatacept, Graft Rejection, Graft Survival, Kidney Transplantation. 27 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Calcineurin inhibitor (CNI) nephrotoxicity drives long‐term kidney‐function decline after simultaneous pancreas‐kidney (SPK) and liver‐kidney (LK) transplantation, but belatacept conversion, as an alternative strategy, is poorly studied in these recipients, whose non‐kidney allograft rejection risk differs.

Methods

We retrospectively studied six SPK and six LK recipients converted from CNI‐ to belatacept‐based immunosuppression and analyzed the cohorts separately alongside a narrative review of published SPK/LK conversion experiences. Outcomes were estimated glomerular filtration rate (eGFR) trajectories and slopes, donor‐specific antibodies (DSA) and rejection, pancreatic, hepatic and metabolic parameters, infections, and survival, reported descriptively with exploratory estimates and 95% confidence intervals (CI).

Results

Conversion occurred a median of 64 (SPK) and 89 (LK) months after transplantation, always with a transient low‐dose CNI overlap (target trough 3‐4 ng/ml). In SPK recipients, median eGFR rose from 45.4 to 55.5 mL/min/1.73m 2 and the median eGFR slope changed from −3.9 to +5.6 mL/min/year (mixed‐model slope change +12.6, 95% CI 2.9 to 22.3); in LK recipients, from 38.8 to 46.3 and from −3.1 to +4.1 (estimate +6.3, 95% CI −4.2 to 16.7). No new DSA developed; pre‐existing DSA declined or remained stable. Pancreatic and liver function stayed stable. Two infections in LK recipients ( Pneumocystis pneumonia, adenovirus) were possibly belatacept‐aggravated. Over a median 25 months, 8/12 (67%) remained on belatacept.

Conclusions

Late belatacept conversion with a transient low‐dose CNI overlap was feasible in selected SPK and LK recipients and was associated with stable‐to‐improved kidney function without a pancreatic or hepatic safety signal. The uncontrolled design supports feasibility, not efficacy.

Subjects

MeSH terms (MEDLINE)

AbataceptGraft RejectionGraft SurvivalKidney TransplantationLiver TransplantationPancreas TransplantationPostoperative ComplicationsAdultFemaleHumansMaleMiddle AgedFeasibility StudiesFollow-Up StudiesGlomerular Filtration RateImmunosuppressive AgentsKidney Function TestsPrognosisRetrospective StudiesRisk Factors

Author keywords

belatacept conversioncostimulation blockadeliver‐kidney transplantationsimultaneous pancreas‐kidney transplantation

Substances

AbataceptImmunosuppressive Agents

Authors and institutions

  • Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Division of Nephrology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
  • Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Cite

APA

Harmacek, D., Rho, E., von Moos, S., Simmler, S., Welte, T., Rössler, F., Schachtner, T., & Weidmann, L. (2026). Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review. Clinical Transplantation. https://doi.org/10.1111/ctr.70719

Vancouver

Harmacek D, Rho E, von Moos S, Simmler S, Welte T, Rössler F, et al. Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review. Clinical Transplantation. 2026. doi:10.1111/ctr.70719

BibTeX
@article{Harmacek2026,
  author = {Harmacek, Dusan and Rho, Elena and von Moos, Seraina and Simmler, Severin and Welte, Thomas and Rössler, Fabian and Schachtner, Thomas and Weidmann, Lukas},
  title = {Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70719}
}
Start for free →